CN1264573C - 抗乙型肝炎病毒人单克隆抗体交联干扰素靶向制剂的制备方法 - Google Patents
抗乙型肝炎病毒人单克隆抗体交联干扰素靶向制剂的制备方法 Download PDFInfo
- Publication number
- CN1264573C CN1264573C CN 03134617 CN03134617A CN1264573C CN 1264573 C CN1264573 C CN 1264573C CN 03134617 CN03134617 CN 03134617 CN 03134617 A CN03134617 A CN 03134617A CN 1264573 C CN1264573 C CN 1264573C
- Authority
- CN
- China
- Prior art keywords
- hepatitis
- human monoclonal
- preparation
- monoclonal antibodies
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000282414 Homo sapiens Species 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 42
- 102000014150 Interferons Human genes 0.000 title claims abstract description 18
- 108010050904 Interferons Proteins 0.000 title claims abstract description 18
- 229940079322 interferon Drugs 0.000 title claims abstract description 18
- 230000008685 targeting Effects 0.000 title claims abstract description 12
- 238000004132 cross linking Methods 0.000 title claims abstract description 5
- 238000000034 method Methods 0.000 title claims description 10
- 241000700721 Hepatitis B virus Species 0.000 title claims description 5
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 11
- 208000002672 hepatitis B Diseases 0.000 claims description 58
- 210000004027 cell Anatomy 0.000 claims description 46
- 210000004408 hybridoma Anatomy 0.000 claims description 43
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 claims description 34
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 15
- 239000002953 phosphate buffered saline Substances 0.000 claims description 15
- 206010003445 Ascites Diseases 0.000 claims description 13
- 210000004988 splenocyte Anatomy 0.000 claims description 11
- 230000028327 secretion Effects 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 9
- 210000000952 spleen Anatomy 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 239000002244 precipitate Substances 0.000 claims description 8
- 238000002965 ELISA Methods 0.000 claims description 7
- 241000699660 Mus musculus Species 0.000 claims description 7
- 238000000502 dialysis Methods 0.000 claims description 7
- 238000011580 nude mouse model Methods 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 7
- 230000007910 cell fusion Effects 0.000 claims description 6
- 238000005119 centrifugation Methods 0.000 claims description 6
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 claims description 6
- 210000000683 abdominal cavity Anatomy 0.000 claims description 5
- 239000012228 culture supernatant Substances 0.000 claims description 5
- 239000003480 eluent Substances 0.000 claims description 5
- 208000007452 Plasmacytoma Diseases 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 238000011081 inoculation Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 229940124872 Hepatitis B virus vaccine Drugs 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 238000000265 homogenisation Methods 0.000 claims description 3
- 238000010255 intramuscular injection Methods 0.000 claims description 3
- 239000007927 intramuscular injection Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 238000005374 membrane filtration Methods 0.000 claims description 3
- 239000008363 phosphate buffer Substances 0.000 claims description 3
- 230000003248 secreting effect Effects 0.000 claims description 3
- 239000012679 serum free medium Substances 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 238000007792 addition Methods 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 238000001641 gel filtration chromatography Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 8
- 241000700605 Viruses Species 0.000 abstract description 7
- 208000006454 hepatitis Diseases 0.000 abstract description 6
- 102000006992 Interferon-alpha Human genes 0.000 abstract 5
- 108010047761 Interferon-alpha Proteins 0.000 abstract 5
- 231100000283 hepatitis Toxicity 0.000 abstract 2
- 229940126585 therapeutic drug Drugs 0.000 abstract 1
- 238000011160 research Methods 0.000 description 10
- 238000011282 treatment Methods 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 7
- 239000000178 monomer Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000011161 development Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001846 repelling effect Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003616 anti-epidemic effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000010494 opalescence Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03134617 CN1264573C (zh) | 2003-09-26 | 2003-09-26 | 抗乙型肝炎病毒人单克隆抗体交联干扰素靶向制剂的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03134617 CN1264573C (zh) | 2003-09-26 | 2003-09-26 | 抗乙型肝炎病毒人单克隆抗体交联干扰素靶向制剂的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1600369A CN1600369A (zh) | 2005-03-30 |
CN1264573C true CN1264573C (zh) | 2006-07-19 |
Family
ID=34659043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03134617 Expired - Fee Related CN1264573C (zh) | 2003-09-26 | 2003-09-26 | 抗乙型肝炎病毒人单克隆抗体交联干扰素靶向制剂的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1264573C (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100376671C (zh) * | 2005-04-30 | 2008-03-26 | 华中科技大学同济医学院附属同济医院 | 抗乙型肝炎病毒表面抗原的杂交瘤细胞株及其单克隆抗体 |
-
2003
- 2003-09-26 CN CN 03134617 patent/CN1264573C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1600369A (zh) | 2005-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1234725C (zh) | 一种高效快速纯化制备片段抗体的方法 | |
CN102120768B (zh) | 利用生物反应器生产治疗性犬细小病毒单克隆抗体的方法 | |
CN105132371B (zh) | 体外提呈、激活dc细胞的方法及其应用 | |
CN1264573C (zh) | 抗乙型肝炎病毒人单克隆抗体交联干扰素靶向制剂的制备方法 | |
CN114539426B (zh) | 一种含干扰素α的融合蛋白、表达该融合蛋白的重组菌株及其制备方法 | |
CN1911963A (zh) | Sars中和性抗体及应用 | |
CN101061136A (zh) | 具有白介素-2中和能力的免疫治疗制剂 | |
CN1242059C (zh) | rDSPAα I 的产生方法 | |
CN1142183C (zh) | 抗独特型微抗体及其制备方法和应用 | |
CN1455813A (zh) | 人骨髓瘤细胞系 | |
CN1194986C (zh) | 丙型肝炎病毒高变区1合成肽及其应用 | |
CN87102457A (zh) | 初级细胞的永久化 | |
CN1600856A (zh) | 分泌抗乙肝人单克隆抗体的异种杂交瘤细胞系的构建方法 | |
CN1803846A (zh) | p53蛋白的表位(SQAMDDLMLS)与丝状噬菌体基因8蛋白的杂合蛋白及其应用 | |
CN1185254C (zh) | 丙型肝炎病毒第一高变区抗原及其融合抗原 | |
CN1721531A (zh) | 重组人抗体表达载体及其应用 | |
CN1164753C (zh) | 抗iv型胶原酶单链抗体与力达霉素辅基蛋白的融合蛋白 | |
CN1616095A (zh) | 减毒株脊髓灰质炎灭活疫苗后处理方法 | |
CN1429908A (zh) | 基因重组乙肝病毒表面抗原的基因修饰序列及其产物 | |
CN1831121A (zh) | 抗乙肝病毒人单克隆抗体的杂交瘤细胞系构建方法及应用 | |
CN1261455C (zh) | 一种重组人源性抗乙肝表面抗原(HBsAg)Fab抗体及其制取方法 | |
CN117304344B (zh) | 一种融合蛋白、表达该融合蛋白的重组菌株及其应用 | |
CN1311257A (zh) | 双特异性单克隆抗体、其制备方法和用其制成的溶血栓剂 | |
CN1059237C (zh) | 重组人肝细胞生成素的生产方法及其治疗严重肝病的用途 | |
JPS59144796A (ja) | 単一クロ−ン抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHAANXI JIUZHOU BIO-MEDICAL TECHNOLOGY PARK DEVELO Free format text: FORMER OWNER: SHAANXI JIUZHOU BIOTECHNOLOGY CO., LTD Effective date: 20100511 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: SHAANXI JIUZHOU BIOTECHNOLOGY CO., LTD Free format text: FORMER NAME: SHAANXI JIUZHOU TECHNOLOGY CO., LTD. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 710075 NO.18, GAOXINER ROAD, XIAN CITY, SHANXI PROVINCE TO: 710065 NO.196, KEJILIU ROAD, XIAN CITY HIGH-TECH ZONE, SHANXI PROVINCE |
|
CP03 | Change of name, title or address |
Address after: 710065 No. six, No. 196, hi tech Zone, Shaanxi, Xi'an Patentee after: SHAANXI JIUZHOU BIOTECHNOLOGY Co.,Ltd. Address before: 710075 No. two, No. 18, hi tech Road, Shaanxi, Xi'an Patentee before: Shaanxi Jiuzhou Technology Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100511 Address after: 710065 No. six, No. 196, hi tech Zone, Shaanxi, Xi'an Patentee after: Shanxi GeoBiopharma Corp. Address before: 710075 No. two, No. 18, hi tech Road, Shaanxi, Xi'an Patentee before: SHAANXI JIUZHOU BIOTECHNOLOGY Co.,Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: SHAANXI JIUZHOU BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: SHAANXI JIUZHOU BIOMEDICINE PARK Effective date: 20130627 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20130627 Address after: 710065 No. six, No. 196, hi tech Zone, Shaanxi, Xi'an Patentee after: SHAANXI JIUZHOU BIOTECHNOLOGY Co.,Ltd. Address before: 710065 No. six, No. 196, hi tech Zone, Shaanxi, Xi'an Patentee before: Shanxi GeoBiopharma Corp. |
|
ASS | Succession or assignment of patent right |
Owner name: SHAANXI JIUZHOU BIOMEDICINE PARK Free format text: FORMER OWNER: SHAANXI JIUZHOU BIOTECHNOLOGY CO., LTD. Effective date: 20130802 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20130802 Address after: 710065 No. six, No. 196, hi tech Zone, Shaanxi, Xi'an Patentee after: Shanxi GeoBiopharma Corp. Address before: 710065 No. six, No. 196, hi tech Zone, Shaanxi, Xi'an Patentee before: SHAANXI JIUZHOU BIOTECHNOLOGY Co.,Ltd. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160525 Address after: 710065 No. six, No. 196, hi tech Zone, Shaanxi, Xi'an Patentee after: SHAANXI JIUZHOU CELL GENE ENGINEERING CO.,LTD. Address before: 710065 No. six, No. 196, hi tech Zone, Shaanxi, Xi'an Patentee before: Shanxi GeoBiopharma Corp. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060719 Termination date: 20210926 |
|
CF01 | Termination of patent right due to non-payment of annual fee |